Baiao Saitu completed a 410-yuan C-round financing to build a CRO company based on genetically modified animal models and comprehensive biomedical research and development.
On April 10th, the 100 Olympics Gene Biotechnology Co., Ltd. ("Bao Sai Tu") announced the completion of a total of 410 million yuan of Series C financing. This round of financing was led by CMB International Capital, and the B-round led the investment of the SDIC, as well as the capital of the company, Tongchuang Weiye and Yuanhe. The funds raised in this round will be mainly used in the fields of domestic and international market development, technology and product development, new base construction, and talent team building.
Founded in 2008, Biotech is a comprehensive research and development based on genetic editing technology, model animal custom development services, large-scale breeding and supply of animal models for special diseases, in vivo pharmacological efficacy evaluation services, and antibody drug research and development outsourcing services. Sexual Biomedical CRO Company.
At present, Biograph has grown into the largest provider of genetically edited animal model services in China, and is also the largest supplier of humanized mice to immunodeficient mice and tumor immunological checkpoints in China. Based on the self-developed tumor immunological checkpoint humanized animals and the severe immune-deficient mice (B-NDG) model reconstructed by the human immune system, the company provides clients with in vivo pharmacological efficacy evaluation services for tumor immunotherapy drugs. Furthermore, based on the unique model animal efficacy evaluation system, the company has greatly accelerated and optimized the antibody discovery process, providing efficient and fast, high success rate antibody drug discovery and screening outsourcing services for domestic and foreign pharmaceutical companies.
As of the end of 2017, Biotech has provided model animal supply, pharmacological efficacy evaluation and antibody research and development to nearly 100 pharmaceutical R&D companies including Amgen, Sanofi, Eli Lilly, Merck and Roche. Outsourcing services; and provide genetic editing customized services for nearly 500 domestic research institutions, universities, pharmaceutical companies, and more than 150 foreign research institutions and universities.
The modern biomedical industry requires standardized model animals and reliable animal models for specific diseases as research and development tools. Model animals and disease animal models are essential for in vivo testing of drugs, and they are the key to translational medicine throughout the various links of the pharmaceutical R&D industry chain. Globally, 3-4 industry giants monopolize the global model animal industry, which in turn affects the development of innovative pharmaceuticals worldwide.
Dr. Shen Yuelei, founder and chairman of Bio-Science, said: “Bao Sai Tu started with the animal editing model animal development business, and later expanded to the special disease animal model preparation, large-scale breeding and supply, and based on this, Pharmacological efficacy evaluation services and antibody drug R&D outsourcing services. In recent years, the rapid development of gene editing technology and the rapid rise of tumor immunotherapy have brought rare opportunities for development of the Biographs. Based on model animals, 100 Ossetia has quickly entered the early development of antibody drugs, and we hope to grow into a world-class comprehensive biomedical R&D service CRO, which will contribute to human health."
When talking about this financing, Dr. Shen Yuelei said: "We are honored that C-round financing has attracted the attention of a large number of investors, and we are fortunate to have come together with CMB International Capital, Materia Medica Capital, Tongchuang Weiye and Yuanhe Origin. 2008 I founded the 100 Olympics in the United States. In the past ten years, the company has grown from a start-up company to a comprehensive multinational CRO company with nearly 600 employees. In addition to the hard work of all employees, we are also grateful to the A-round investor Baiao Wealth Fund. With the strong support of the B-round leader of the investment in the SDIC, looking forward to the future, I believe that the completion of the C-round financing will help push the business of the Pharmacy to a new height."
As the lead investor in C-round financing, Zhou Kexiang, managing director of CMB International Capital, believes: “In the next five years, global drug research and development expenditure will continue to increase, and the pharmaceutical CRO industry is a direct beneficiary; Chinese pharmaceutical CRO companies participate in the global R&D division, the future It will continue to maintain rapid development. The vigorous development of China's original drug research and development enterprises will also promote the rapid rise of China's pharmaceutical CRO industry. As a comprehensive bio-pharmaceutical CRO company, Bio-Saitu is solidly based and we are very happy to support the BIO. Further development."
Gao Aimin, general manager of the B-round leader of SDIC Ventures, said that he has continued to participate in the C-round financing: "In the past three years, the 100 Olympics has made great progress. As the B-round leader of the BIO, it is an honor to participate and Witnessed the rapid development of the company. The model animal industry is the basis for the research and development of new drugs, and it is the bottleneck that restricts the research and development of innovative drugs in China for a long time. As the manager of the major special achievement transformation fund of the Ministry of Science and Technology, we hope to cultivate and support national enterprises to become a global model. The leader in the field of animals promotes the development of the entire Chinese biomedical industry."
Dr. Liu Qianye, founding partner of the investment company Herbal Capital, said: "The tumor immune checkpoint is the main research direction of international tumor immunotherapy. The immunoassay monoclonal antibody is expected to reach nearly 13 billion US dollars by 2020. In the market, the compound growth rate of 27% in the past five years. The company has global advantages in the fields of humanized animal supply and pharmacological efficacy evaluation at the immunization checkpoint, and its development prospect is far-reaching."
Yan Bin, the investment director of Tongchuang Weiye, agreed with the investment side. “Compared with foreign counterparts, the company has embarked on a different development path. This is the correct path along with the development of China’s biomedical industry. We are willing to join and Work hard with a common goal." Zhao Qun, a partner of the investment Yuan Yuanhe, said: "We are very optimistic about the huge platform value of the 100 Olympic Games, willing to support its rapid development, and through various forms of strategic cooperation, jointly promote the development of domestic antibody drug research and development."
We're Professional Supplier Extract Powder manufacturers and suppliers in China specialized in providing high-quality products at low price. We warmly welcome you to buy or wholesale bulk Supplier Extract Powder for sale here from our factory. For a free sample, contact us now.
Supplier Extract Powder,Supplier Extract ,Supplier Powder Manufacturer in China
Shaanxi Kang New Pharmaceutical co., Ltd. , https://www.kangnewpharmas.com